Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Compare the Accuracy of Circulating Tumor DNA Longitudinal Monitoring Minimal Residual Disease and Microvascular Invasion Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma

NCT06449846 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT06449846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06449846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Compare the Accuracy of Circulating Tumor DNA Longitudinal Monitoring Minimal Residual Disease and Microvascular Invasion Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
Lead sponsor
Zhujiang Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
June 1, 2024
Completion date
December 31, 2026
Enrollment
152 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma resectable, recurrence, surgery